Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics, Inc.

Marker Therapeutics is engaged in developing novel T-cell therapies targeted at blood cancers and solid tumors. The company's proprietary Multi-Antigen Recognizing (MAR) T cell technology allows for the recognition and targeting of tumor cells without genetic modifications, with a focus on safety and efficacy in various clinical indications.

Marker Therapeutics

Marker Therapeutics, Inc. | 4,075 followers on LinkedIn. Pioneering a Multi-Antigen Approach | We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity.

Wilson Wolf CEO focused on solving cell and gene therapy manufacturing challenges

John Wilson

Senior Human Resources Manager at Marker Therapeutics, Inc.

Nina Sisommout, SHRM-CP

Clinical Project Manager at Marker Therapeutics

Molly Gilbert

Immunologist/Cancer Biologist

Laura S Angelo

📢 Today we reported our third quarter 2024 financial results and provided business updates. Follow the link for more information: https://lnkd.in/g-bjC4Jt #multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

📢 Today we reported our second quarter 2024 financial results and provided business updates. Follow the link for more information: https://lnkd.in/gDjQfatn #multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

NEWS 💥 NEWS 💥 NEWS! Marker Therapeutics was awarded a $2 million grant from the #NIH Small Business Innovation Research ( #SBIR ) program! ✨ The proceeds of this award will support our Phase 1 APOLLO study, investigating the #safety and #efficacy of MT-601 in patients with non-Hodgkin’s lymphoma who have relapsed following anti-CD19 CAR-T cell therapy. For more information: https://lnkd.in/gHPjgKUf #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Today we announced that Dr. Shouse, the Principal Investigators at City of Hope , was invited to present his experience from our clinical study in patients with #lymphoma (APOLLO study) at the 11th Global Summit on Hematologic Malignancies. Marker’s Phase 1 #APOLLO study is investigating MT-601, a #multiTAA -specific T cell product, for the treatment of patients with #lymphoma who have #relapsed or are #ineligible to receive #CAR T cell therapy. Key Highlights: 🌟 Three patients were treated at City of Hope as part of the #APOLLO study. 🌟 First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed 4 prior lines of therapy, including a relapse within 90 days of CAR T cell therapy. This participant achieved a #CompleteResponse 8 weeks after the second infusion of MT-601 and remains in complete response #9 #months after initial treatment with MT-601. 🌟 Another study participant was diagnosed with follicular lymphoma that transformed into DLBCL. This participant failed 12 lines of therapy, including CAR T cells. 8 weeks after treatment with MT-601, the study participant achieved a #CompleteResponse , which is maintained 3 months following initial treatment with MT-601. 🌟 The third study participant treated at City of Hope had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a #PartialResponse 8 weeks after MT-601 treatment with all lesions decreasing in size including one that has completely resolved. 🌟 Treatment was well tolerated among all patients with no significant treatment-related adverse events. For more information: https://lnkd.in/gVgUburj #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical studies. 📅 Date: March 26, 2024 ⏰ Time: 10:00 AM, EDT Don’t miss out! Your virtual seat awaits here: https://lnkd.in/dx_JUSBm During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical developments, recent achievements, and anticipated milestones. For more information: https://lnkd.in/gkC_h5Uf #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

We are thrilled to present at the H.C. Wainwright & Co., LLC 2nd Annual Cell Therapy Virtual Conference on March 26, 2024! Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical programs. 📅 Date: March 26, 2024 🕙 Time: 10:00 AM, EDT 👉 Register here: https://lnkd.in/dSQTZqkm The presentation will be available for replay starting March 26, 2024 on the Company’s IR website under Events & Presentations. During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical development, recent achievements, and anticipated milestones. For more information: https://lnkd.in/gkC_h5Uf #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

💥 Breaking News! Today we announced that the United States Adopted Names ( #USAN ) Council and the World Health Organization ( #WHO ) International Nonproprietary Names ( #INN ) expert committee approved “neldaleucel” as the nonproprietary (generic) name for MT-601, our #multiTAA -specific T cell product candidate for the treatment of patients with #lymphoma . Follow the link for more information: https://lnkd.in/gnjjXXvB #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech

📢 Exciting News! Today we announced clinical program updates! Key Highlights: 🌟 Strategic prioritization of clinical programs with a focus on MT-601 in CAR relapse patients with #lymphoma based on promising non-clinical and clinical data. 🌟 Promising clinical observations and new directions with MT-401 in patients with #MRD (measurable residual disease) in #AcuteMyeloidLeukemia (AML). For more information click here: https://lnkd.in/gKyPUKeN #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #patients #cancer #biotech #PancreaticCancer

Meet us in San Francisco during J.P. Morgan week from January 8-10! We are excited to kick off the new year with #JPM ! ✨ If you are attending #JPM2024 and want to connect with our team, please contact us. #SanFrancisco #multiTAAs #biotech #innovation #cancer #immunotherapy #AML #lymphoma #healthcare

We are honored to be recognized as part of the 2023 FreeMind Elite! 🌟 The FreeMind Elite is a selection of FreeMind Group clients who have excelled in securing non-dilutive funding and developing medical technologies in the life sciences sector over the past year. Thank you FreeMind Group for this recognition and our existing partnership! 🎉🙌 #FreeMindElite #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #lymphoma #AML #patients #cancer #biotech

msh id	COM:MARKERTHERAPEUTICS
symbol	MRKR
name	Marker Therapeutics, Inc.
homepage url	https://www.markertherapeutics.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	8
crunchbase url	-
linkedin url	-
founders	-

market cap	44.42M
enterprise value	-
stage	Grant
raised capital	2M
valuation	-

monthly webtraffic	4.75K
monthly webtraffic growth	-0.22
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-0.54
growth cost of revenue	-1
growth depreciation and amortization	-1
growth ebitda	0.44
growth ebitda ratio	-0.51
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-0.42
growth gross profit	-0.38
growth gross profit ratio	0.69

COM:MARKERTHERAPEUTICS

Marker Therapeutics

Last Close

3.18

21/11 21:00

Market Cap

44.42M

Beta: -

Volume Today

41.89K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	17.89M
cost of revenue	17.89M
depreciation and amortization	2
ebitda	-14.58M
ebitda ratio	-4.4
eps	-1.93
eps diluted	-1.93
operating expenses	17.89M
operating income	-14.58M
operating income ratio	-4.4

accounts receivables	1.37M
capital expenditure	-
cash at beginning of period	11.78M
cash at end of period	15.11M
inventory	1
working capital ttm	16.71M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-